missing translation for 'onlineSavingsMsg'
Learn More
Learn More
CDC42BPA Monoclonal Antibody (OTI7B9), TrueMAB™, OriGene
Mouse Monoclonal Antibody
Brand: Origene Technologies TA808223S
This item is not returnable.
View return policy
Description
CDC42BPA Monoclonal antibody specifically detects CDC42BPA in Human samples. It is validated for Western BlotSpecifications
| CDC42BPA | |
| Monoclonal | |
| 1 mg/mL | |
| PBS with 1% BSA, 50% glycerol and 0.02% sodium azide | |
| Q5VT25 | |
| Mouse | |
| Affinity chromatography | |
| RUO | |
| 8476 | |
| -20° C, Avoid Freeze/Thaw Cycles | |
| IgG1 |
| Western Blot | |
| OTI7B9 | |
| Unconjugated | |
| CDC42BPA | |
| A930014J19Rik; CDC42 binding protein kinase alpha; CDC42 binding protein kinase alpha (DMPK-like); CDC42 binidng protein kinase beta; CDC42-binding protein kinase alpha; CDC42-binding protein kinase alpha (DMPK-like); CDC42BPA; cdc42bpa {ECO:0000250; DKFZp686L1738; DKFZp686P1738; DMPK-like; DMPK-like alpha; FLJ23347; Kiaa0451; MRCK; MRCK alpha; MRCKA; myotonic dystrophy kinase-related CDC42-binding kinase alpha; myotonic dystrophy kinase-related CDC-42-binding kinase-alpha; myotonic dystrophy kinase-related CDC42-binding protein kinase alpha; myotonic dystrophy protein kinase-like alpha; mytonic dystrophy kinase-related Cdc42-binding kinase; PK428; RP5-1087E8.4; serine/threonine-protein kinase MRCK alpha; ser-thr protein kinase PK428; ser-thr protein kinase related to the myotonic dystrophy protein kinase; UniProtKB:Q5VT25} | |
| Human recombinant protein fragment corresponding to amino acids 1419-1638 of human CDC42BPA produced in E.coli. | |
| 30 μL | |
| Primary | |
| Human | |
| Liquid |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction